Stem cell surgery options and procedures continue to evolve at a rapid rate and companies such as Cytori Therapeutics are making preparations to serve more medical centers and cosmetic surgery facilities with stem cell orders in the oncoming years. Most recently, Cytori has received an order for a StemSource Cell Bank from Cosmetic Surgery Seishin in Japan. Read more…
Results emanated from an independent study evaluating the use of Hextend® in hemodynamically unstable trauma patients. Hextend (6% Hetastarch in Lactated Electrolyte Injection) is BTIM’s commercially-available blood plasma volume expander used to treat hypovolemia (low blood volume). The study reported that initial resuscitation with Hextend was associated with NO obvious coagulopathy and reduced mortality compared to fluid resuscitation without Hextend. Read more…
The turmoil in the last 2-3 weeks markets makes it hard sometimes to focus GERN’s short-term share price appreciation. An expanding indication for GRNOPC1 is good news as the FDA placed a clinical hold on the early-stage trial of this compound. The outstanding warrant exchange accounting for approximately 3/4 of all warrants strengthened the balance sheet with GERN selling additional shares of common to investors at a premium for gross proceeds of $10 M, generating a 2.7 M shares lock-up provision with the new block of shares being purchased and issuance of a call option to the investors to purchase an additional $5 M of common stock. Read more…
ReNeuron is a UK-based stem cell company. Their primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. RENE.L’s shares are traded on the London AIM market.
Read more…
Results from Cytori Therapeutics’ preclinical fat grafting study have been published in the February issue of the Annals of Plastic Surgery. This article, entitled “Supplementation of Fat Grafts with Adipose-Derived Regenerative Cells (ADRCs) Improves Long-Term Graft Retention,” examines the science behind cell-enriched autologous fat grafting and its application to cosmetic and reconstructive surgery.
Read more…
Cytori Therapeutics received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the CYTX’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient’s breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body and broadens current expansive patent portfolio covering adipose-derived cell therapies.
Read more…
MultiCell Immunotherapeutics specializes in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery by leveraging patented technology and expertise to develop therapeutics to treat serious diseases including multiple sclerosis, type-1 diabetes, and infectious disease.
Read more…
The public offering/ financing further strengthened its’ balance sheet and to complete ongoing Phase II clinical trials:
- Receiving approximately $12.4 M from the sale of units including the over-allotment,
- The 52,077,100 units consisted of 52,077,100 shares of common stock, Class A Warrants to purchase an aggregate of 39,057,825 shares of common stock and Class B Warrants to purchase an aggregate of 26,038,550 shares of common stock, Read more…
ASTM announced, 1/14/10 that it intends to offer to sell, subject to market and other conditions, units consisting of shares of its common stock, Class A warrants and Class B warrants, in an underwritten public offering. Read more…
There are 337 (276 public and 61 private) lifescience companies presenting starting Monday, 1/11 and running through Thursday, 1/14. Link: JPMHealthcareConference-Agenda1.7
Public company presentations are usually web-cast enabling non-participants to view presentations with breakout sessions immediately following their presentations. These web-casts will be available for 3 months after the conference: https://events.jpmorgan.com/ ; so click on the web-cast link (no need for a user name and password but will be prompted an email address). As related to current economic times, registration of attendees was limited by JP Morgan to a total of about 3,500 versus 6,000 in the past years.
Read more…
